Skip to main content
Top
Published in: Tumor Biology 8/2014

01-08-2014 | Research Article

Prognostic value of CYP2W1 expression in patients with human hepatocellular carcinoma

Authors: Ke Zhang, Li Jiang, Rong He, Bao-Liang Li, Zhe Jia, Rong-Hai Huang, Yi Mu

Published in: Tumor Biology | Issue 8/2014

Login to get access

Abstract

CYP2W1 overexpression has been reported in a variety of human cancers. However, the role of CYP2W1 in hepatocellular carcinoma (HCC) remains unclear. This study was designed to evaluate the expression and prognostic significance of CYP2W1 in human HCC. Real-time quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was conducted to detect CYP2W1 messenger RNA (mRNA) expression in 41 pairs of fresh-frozen HCC tissues and adjacent noncancerous tissues. In addition, CYP2W1 expression was analyzed by immunohistochemistry in 133 clinicopathologically characterized HCC cases. The relationship between CYP2W1 expression and clinicopathological features was analyzed by appropriate statistics. Kaplan-Meier analysis and Cox proportional hazards regression models were used to investigate the correlation between CYP2W1 expression and prognosis of HCC patients. The relative mRNA expression of CYP2W1 was significantly higher in HCC tissues than in adjacent noncancerous tissues (P < 0.001). In addition, CYP2W1 expression was significantly correlated with tumor size (P = 0.023), histological differentiation (P = 0.04), and tumor stage (P = 0.014). The Kaplan-Meier survival curves indicated that patients with high expression of CYP2W1 had shorter overall survival than those with low expression (P < 0.001). Furthermore, Cox regression analyses showed that CYP2W1 expression was an independent predictor of overall survival. Our data suggest that CYP2W1 could play an important role in HCC and might serve as a valuable prognostic marker and potential target for gene therapy in the treatment of HCC.
Literature
3.
go back to reference Karlgren M, Gomez A, Stark K, Svärd J, Rodriguez-Antona C, Oliw E, et al. Ramón y Cajal S, Johansson I, Ingelman-Sundberg M. Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochem Biophys Res Commun. 2006;341:451–8.PubMedCrossRef Karlgren M, Gomez A, Stark K, Svärd J, Rodriguez-Antona C, Oliw E, et al. Ramón y Cajal S, Johansson I, Ingelman-Sundberg M. Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochem Biophys Res Commun. 2006;341:451–8.PubMedCrossRef
4.
go back to reference Edler D, Stenstedt K, Ohrling K, Hallström M, Karlgren M, Ingelman-Sundberg M, et al. The expression of the novel CYP2W1 enzyme is an independent prognostic factor in colorectal cancer—a pilot study. Eur J Cancer. 2009;45:705–12. doi:10.1016/j.ejca.2008.11.031.PubMedCrossRef Edler D, Stenstedt K, Ohrling K, Hallström M, Karlgren M, Ingelman-Sundberg M, et al. The expression of the novel CYP2W1 enzyme is an independent prognostic factor in colorectal cancer—a pilot study. Eur J Cancer. 2009;45:705–12. doi:10.​1016/​j.​ejca.​2008.​11.​031.PubMedCrossRef
5.
go back to reference Stenstedt K, Hallstrom M, Johansson I, Ingelman-Sundberg M, Ragnhammar P, Edler D. The expression of CYP2W1: a prognostic marker in colon cancer. Anticancer Res. 2012;32:3869–74.PubMed Stenstedt K, Hallstrom M, Johansson I, Ingelman-Sundberg M, Ragnhammar P, Edler D. The expression of CYP2W1: a prognostic marker in colon cancer. Anticancer Res. 2012;32:3869–74.PubMed
7.
go back to reference Du L, Hoffman SM, Keeney DS. Epidermal CYP2 family cytochromes P450. Toxicol Appl Pharmacol. 2004;195:278–87.PubMedCrossRef Du L, Hoffman SM, Keeney DS. Epidermal CYP2 family cytochromes P450. Toxicol Appl Pharmacol. 2004;195:278–87.PubMedCrossRef
8.
go back to reference Du L, Neis MM, Ladd PA, Lanza DL, Yost GS, Keeney DS. Effects of the differentiated keratinocyte phenotype on expression levels of CYP1-4 family genes in human skin cells. Toxicol Appl Pharmacol. 2006;213:135–44.PubMedCrossRef Du L, Neis MM, Ladd PA, Lanza DL, Yost GS, Keeney DS. Effects of the differentiated keratinocyte phenotype on expression levels of CYP1-4 family genes in human skin cells. Toxicol Appl Pharmacol. 2006;213:135–44.PubMedCrossRef
9.
go back to reference Du L, Neis MM, Ladd PA, Keeney DS. Differentiation-specific factors modulate epidermal CYP1-4 gene expression in human skin in response to retinoic acid and classic aryl hydrocarbon receptor ligands. J Pharmacol Exp Ther. 2006;319:1162–71. doi:10.1124/jpet.106.111724.PubMedCrossRef Du L, Neis MM, Ladd PA, Keeney DS. Differentiation-specific factors modulate epidermal CYP1-4 gene expression in human skin in response to retinoic acid and classic aryl hydrocarbon receptor ligands. J Pharmacol Exp Ther. 2006;319:1162–71. doi:10.​1124/​jpet.​106.​111724.PubMedCrossRef
12.
go back to reference Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, et al. A decade’s studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:187–96.PubMedCrossRef Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, et al. A decade’s studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:187–96.PubMedCrossRef
14.
go back to reference Zhou J, Tang ZY, Wu ZQ, Zhou XD, Ma ZC, Tan CJ, et al. Factors influencing survival in hepatocellular carcinoma patients with macroscopic portal vein tumor thrombosis after surgery, with special reference to time dependency: a single-center experience of 381 cases. Hepatogastroenterol. 2006;53:275–80. Zhou J, Tang ZY, Wu ZQ, Zhou XD, Ma ZC, Tan CJ, et al. Factors influencing survival in hepatocellular carcinoma patients with macroscopic portal vein tumor thrombosis after surgery, with special reference to time dependency: a single-center experience of 381 cases. Hepatogastroenterol. 2006;53:275–80.
Metadata
Title
Prognostic value of CYP2W1 expression in patients with human hepatocellular carcinoma
Authors
Ke Zhang
Li Jiang
Rong He
Bao-Liang Li
Zhe Jia
Rong-Hai Huang
Yi Mu
Publication date
01-08-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 8/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2023-9

Other articles of this Issue 8/2014

Tumor Biology 8/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine